Citation

Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F, Rey D, Peyramond D, Gourdon F, Drobacheff C, Lombart ML, Lucht F, Besnier JM, Bernard L, Chavanet P, Portier H. J. Vira.l Hepat. 2000; 7(4): 302-308.

Copyright

(Copyright © 2000, John Wiley and Sons)

DOI

10.1046/j.1365-2893.2000.00227.x

PMID

10886541

Abstract

A longitudinal study of human immunodeficiency virus (HIV)-infected individuals followed-up in 13 centres was performed to assess the influence of hepatitis C virus (HCV) on the clinical and immunological evolution of HIV-infected patients. Eight-hundred and twelve HIV-infected patients with known HIV acquisition date, 89 co-infected with HCV, were included in the cohort. Clinical progression was defined as: 30% decrease of Karnofsky's index; and/or 20% body weight loss; and/or acquired immune deficiency syndrome (AIDS)-defining illness; and/or death (except by accident, suicide, or overdose). Immunological progression was defined as a decrease of initial CD4 count to below 200 mm(-3). If immunological progression was not statistically different between groups (P=0.25), clinical progression was significantly faster in HCV-HIV co-infected patients in univariate (P=0.02) and multivariable survival analysis (hazard ratio=1.63, P=0.03). This argues for active management of hepatitis C chronic infection among HCV-HIV co-infected patients.

Language: en

Keywords

Humans; Adult; Female; Male; Time Factors; Cohort Studies; Longitudinal Studies; France; Prognosis; HIV-1; CD4 Lymphocyte Count; Hepatitis C/*complications; HIV Infections/*complications/etiology/immunology